A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

South Korea

The Catholic Univ. of Korea Eunpyeong St. Mary's Hospital, Seoul